Published in Managed Care Business Week, August 1st, 2006
The results of these studies demonstrated that ACP-104 is safe and well tolerated after repeated dosing of up to 600 mg per day, and that initial signals of antipsychotic effects were observed within the tolerated dose range of ACP-104. In addition, plasma levels of ACP-104 correlate with brain receptor occupancies indicating good penetration of ACP-104 into the brain. The...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Business Week